Vectus Biosystems Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	9.2yrs

Recente managementupdates

Recent updates

Will Vectus Biosystems (ASX:VBS) Spend Its Cash Wisely?

Mar 08

Our Take On Vectus Biosystems' (ASX:VBS) CEO Salary

Dec 31

CEO

Vectus Biosystems heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Maurie Stang	Non-Executive Deputy Chairman	18.9yrs	AU$55.00k	9.17% A$ 390.8k
Ronald Shnier	Non-Executive Chairman	9.2yrs	AU$65.00k	0.65% A$ 27.7k
Susan Pond	Non-Executive Director	8.5yrs	AU$45.00k	0.076% A$ 3.2k

9.2yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van VBS wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.2 jaar).

Vectus Biosystems Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024

No independent directors

Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023

No independent directors

No independent directors

Vectus Biosystems Limited, Annual General Meeting, Nov 23, 2022

Recent updates

Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024

Full year 2024 earnings released: AU$0.044 loss per share (vs AU$0.072 loss in FY 2023)

New major risk - Financial position

No independent directors

Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023

Full year 2023 earnings released: AU$0.072 loss per share (vs AU$0.12 loss in FY 2022)

No independent directors

New major risk - Share price stability

Will Vectus Biosystems (ASX:VBS) Spend Its Cash Wisely?

First half 2023 earnings released: AU$0.05 loss per share (vs AU$0.08 loss in 1H 2022)

Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 3.65307 million.

No independent directors

Vectus Biosystems Limited, Annual General Meeting, Nov 23, 2022

Vectus Biosystems Limited Announces Completion of Phase Ia for VB0004

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.15 loss in FY 2021)

Vectus Biosystems Limited Announces Completion of Second M.A.D. Study for Vb0004

Vectus Biosystems Limited Announces Completion of Final Single Ascending Dose Study and First Multiple Ascending Dose Study for VB0004

Less than half of directors are independent

Vectus Biosystems Limited Announces Fourth of the Five Planned Cohorts in the Single Ascending Dose Segment of Its First-In-Human Tria

Vectus Biosystems Limited Announces Third S.A.D. Group Reviewed by Trial Safety Review Committee

Independent Non-Executive Chairman exercised options to buy AU$277k worth of stock.

Full year 2021 earnings released: AU$0.15 loss per share (vs AU$0.13 loss in FY 2020)

Vectus Biosystems Limited Announces Successful Completion of First Group in Phase I Human Trial

Approval Receives Approval from the Human Research Ethics Committee for Phase I Trial in Australia

Our Take On Vectus Biosystems' (ASX:VBS) CEO Salary

New 90-day high: AU$1.16

Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 7 million.

Full year earnings released - AU$0.13 loss per share

CEO

Bestuursleden

Gemiddelde duur